Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strengthened long-term management of hyperkalemia in hemodialysis patients using sodium zirconium cyclosilicate
ChiCTR2600119050Phase 4Recruiting
- Sponsor
- First People's Hospital of Lin'an District, Hangzhou
- Start
- Feb 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia and end-stage kidney disease (ESKD) (2 arms), sponsored by First People's Hospital of Lin'an District, Hangzhou. Primary endpoint: Serum potassium. Started Feb 2026; status: recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2600119050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119050.